Drug Topics
FEBRUARY 13, 2024
Drug Topics talked with Gregg Sylvester, MD, chief health officer and vice president of medical affairs at CSL Seqirus, about what can we learn from this unique situation to improve future vaccine development and distribution.
Pharmacy Times
FEBRUARY 15, 2024
Since the first FDA biosimilar approval of filgrastim-sndz (Zarxio) in 2015, a total of 44 biosimilars for 15 originator products have been approved and more than 20 are marketed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
FEBRUARY 14, 2024
Discover how artificial intelligence (AI) is revolutionising the drug development process and transforming the way FDA-approved drugs are produced, ensuring compliance and optimising the supply chain. Learn more about the future of AI in pharmaceuticals.
Fierce Healthcare
FEBRUARY 12, 2024
As the use of artificial intelligence technology in healthcare grows, federal lawmakers are weighing how to protect patients without hindering innovation and many in Congress are pushing for strong | As the use of artificial intelligence technology in healthcare grows, federal lawmakers are weighing how to protect patients without hindering innovation and many in Congress are pushing for stronger regulation.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Drug Topics
FEBRUARY 15, 2024
Innovation in the vaccine area continues. In 2023, the FDA approved six vaccines, including several important firsts. But they face a difficult landscape where federal policies dictate coverage.
Pharmacy Times
FEBRUARY 13, 2024
If approved, this would mark the first MDMA-assisted therapy and psychedelic-assisted therapy approved, calling for a reschedule of MDMA from Schedule I. A PDUFA was set for this summer.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Pharmaceutical Technology
FEBRUARY 12, 2024
The UK MHRA has granted approval for a variation in licence of Pfizer-BioNTech’s Comirnaty XBB.1.5 vaccine targeting Omicron variant.
Drug Topics
FEBRUARY 13, 2024
Many patients with the condition continue to experience severe hypoglycemic events even with the use of continuous glucose monitors and other disease management tools.
Pharmacy Times
FEBRUARY 15, 2024
Sustained cognitive improvement is likely a result of lower inflammation, remission of comorbidities, higher physical activity, and better mood.
STAT
FEBRUARY 15, 2024
More than 100,000 doctors have left private practice and become employees of hospitals and other corporate entities since 2019. Today, nearly three in four physicians are employees of larger health care entities or other corporations — a record high. As an independent physician, I know exactly why so many are making that choice.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Fierce Pharma
FEBRUARY 16, 2024
The T-cell therapy treatment class, which has transformed the treatment of certain blood cancers, has now reached the solid tumor field thanks to an FDA approval for a first-of-its-kind immunothera | The T-cell therapy treatment class, which has transformed the treatment of certain blood cancers, has now reached the solid tumor field thanks to an FDA approval for a first-of-its-kind immunotherapy developed by Iovance Biotherapeutics.
Fierce Healthcare
FEBRUARY 14, 2024
As more and more rural hospitals find their operations dropping into the red, the rising enrollment of rural residents in Medicare Advantage plans could pull these providers under, healthcare advis | A new analysis found the largest-ever single-year jump in rural hospitals operating in the red and a nearly 50% rise in Medicare Advantage enrollment over the past five years.
Pharmacy Times
FEBRUARY 14, 2024
Despite the growth in vaccine and antibody development for combatting RSV, lower income countries may not reap the benefits.
STAT
FEBRUARY 16, 2024
Nearly four decades after its first conception, the first TIL therapy, an immunotherapy that harvests cancer-fighting immune cells from the patient’s own body, received accelerated approval from the Food and Drug Administration for advanced melanoma. The therapy, called Amtagvi or lifileucel from Iovance, is the first cell therapy approved for a solid tumor.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Fierce Pharma
FEBRUARY 16, 2024
People with food allergies finally have a drug that can help prevent severe outcomes—and it’s a drug that’s been on the market for two decades. | People with food allergies finally have a drug that can help prevent severe outcomes—and it’s a drug that’s been on the market for two decades. The FDA has blessed Roche and Novartis’ Xolair as the first medicine to reduce allergic reactions that can occur with accidental exposure to certain foods.
Fierce Healthcare
FEBRUARY 12, 2024
Providers working in hospitals and critical access hospitals may now text patient information and patient orders among care team members without landing on the wrong side of Medicare’s Conditions o | Texting patient info has been against Medicare's Conditions of Participations for over half a decade, due to concerns of insecure texting platforms.
Pharmacy Times
FEBRUARY 16, 2024
Pharmacists can host community events and try different marketing efforts to drive community awareness about heart health and total health.
STAT
FEBRUARY 12, 2024
Super Bowl ads are a show within the show, an opportunity for brands and advertising creatives to put their work in front of more than 100 million viewers. And while the occasion is most closely associated with ads for beer, cars, and soft drinks, pharma giant Pfizer dished out millions of dollars for its own message: “Here’s to science.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
pharmaphorum
FEBRUARY 12, 2024
Medicxi has combined six biotechs with dermatology medicines in development in a single drugmaker, called Alys Pharma, which starts life with $100 million in financing.
Fierce Healthcare
FEBRUARY 12, 2024
Kaiser Permanente wrapped up its fiscal year with $329 million of operating income (0.3% operating income), net income of $4.1 billion and more than $100 billion in both operating revenues and expe | The California-based nonprofit noted cost pressures, labor challenges and membership declines but still logged a 0.3% operating income in the wake of 2022's losses.
Pharmacy Times
FEBRUARY 14, 2024
Continued doses of denosumab reduced the incidence of diabetes by more than 1000 patients compared to an initial dose alone.
STAT
FEBRUARY 12, 2024
A growing body of data show that South Asians are at greater risk of developing heart disease than white people, and they tend to get complications at younger ages, but it’s not been fully clear what explains this disparity. A new study suggests one potential reason is that South Asians have a decreased ability to repair blood vessels that get injured from cardiovascular problems.
pharmaphorum
FEBRUARY 16, 2024
Patterns of behaviour: Using AI-based algorithms to improve outcomes for patients with atrial fibrillation Mike.
Fierce Healthcare
FEBRUARY 13, 2024
Most alarms triggered by hospital staff’s wearable safety alert systems occurred outside of the emergency department and more often during weekdays, non-holidays, surges of COVID-19 and even during | Aggregate data from 200,000 workers' wearable duress systems suggest emerging or active violent incidents occur "throughout every part of the hospital," and are more frequent during weekdays, COVID-19 surges and full moons.
Pharmacy Times
FEBRUARY 12, 2024
The FDA approval marks the first and only FDA-approved oral therapy for this patient population, and the drug is expected to be available by the end of February.
STAT
FEBRUARY 12, 2024
There was a time when an allegation of data mishandling, scientific misconduct, or just a technical error felt like a crisis to Barrett Rollins, an oncologist and research integrity officer at Dana-Farber Cancer Institute. Now, it’s a Tuesday. The renowned cancer treatment and research center is in the midst of a lengthy review of possible discrepancies involving around 60 papers co-authored by four of its top researchers over a period of over 15 years, including CEO Laurie Glimcher and C
pharmaphorum
FEBRUARY 12, 2024
Investing in women's health research and funding is not a charity, but a priority. Discover the importance of allocating resources and supporting initiatives that promote women's health and well-being.
Fierce Healthcare
FEBRUARY 16, 2024
Nearly all healthcare executives believe new digital health technologies are worth the cost, even though they have yet to see a financial return from it, a new survey reveals. | Nearly all healthcare executives believe technology is worth the cost, even though they have yet to see a financial return from it, according to a new survey from EY. Most believe in its power to reduce costs and boost provider credibility.
Pharmacy Times
FEBRUARY 12, 2024
AI can pair people to foods that are best suited for their unique needs, according to a food-as-medicine entrepreneur.
STAT
FEBRUARY 15, 2024
WASHINGTON — A new trove of internal emails and other documents from the e-cigarette maker Juul reveals the company’s extensive behind-the-scenes efforts to promote its interests in Washington — a rare insight into the otherwise opaque methods corporations use to influence the government. It’s well documented that Juul spent significant sums on registered lobbyists and political donations back in 2018 and 2019, when the head of the Food and Drug Administration declare
pharmaphorum
FEBRUARY 16, 2024
Gilead Sciences has paused enrolment in clinical trials of its CD47 drug magrolimab in solid tumours, a week after dropping it for blood cancers.
Fierce Healthcare
FEBRUARY 12, 2024
The Federal Trade Commission has secured a $195 million judgement against Florida-based insurer Simple Health following allegations that it sold "sham" coverage to consumers. | The Federal Trade Commission has secured a $195 million judgement against Florida-based insurer Simple Health following allegations that it sold "sham" coverage to consumers.
Pharmacy Times
FEBRUARY 12, 2024
Despite the tool’s ability to predict efficacy of sertraline in patients with major depressive disorder, the investigators note that future research will seek to improve the algorithm.
Expert insights. Personalized for you.
201 
Let's personalize your content